Laddar populära aktier...
Redeye comments on Scandion Oncology’s Q3 2024 report, and we judge a potential partnership or similar is its best hope of advancing SCO-101...
Redeye comments on Scandion Oncology’s Q2 2024 report, shortly after the company announced that its CORIST part 3 extension trial reached MT...
Redeye comments on Scandion Oncology’s Q1 2024 report, shortly after the company announced final terms of its rights issue to fund its CORIS...
Redeye provides its initial take on Scandion Oncology's Q1 2024 report.
Redeye comments on Scandion Oncology announcing a cSEK60m rights issue.
Redeye comments on Scandion Oncology’s Q4 2023 report, with the company having recently presented its plan to drive SCO-101 towards a random...
Redeye comments on Scandion Oncology presenting more details on CORIST part 3 results at its recent investor and R&D event.
Redeye provides its initial take on Scandion Oncology communicating phase IIa CORIST part 3 top-line data.
Redeye comments on Scandion Oncology’s Q3 2023 report, one day after the company announced intriguing final data from CORIST part 2.
Redeye comments on Scandion Oncology’s Q2 2023 report, and we judge that CORIST part 4 data in 2024e is the primary catalyst for the company...
Q123 has been an active quarter for Scandion Oncology with completion of the Phase 1b PANTAX (dose-finding) study and management’s decision ...
Redeye comments on Scandion Oncology’s Q1 2023 report, which follows a first quarter where the company delivered PANTAX phase Ib top-line da...
Scandion Oncology has announced that the Phase Ib PANTAX trial has concluded and reached its primary endpoint.
Redeye is encouraged by PANTAX phase Ib top-line data aligning with our expectations.
In the recent management conference call to summarise the FY22 results, Scandion Oncology announced plans to expand SCO-101, its lead asset,...
Scandion’s Q422 and FY22 results highlighted the significance of the upcoming year, with key clinical milestones expected for its lead asset...
Redeye comments on Scandion Oncology’s Q4 2022 report, with a new CEO in place and two study readouts in 2023e.
Scandion Oncology has announced the appointment of Francois Martelet, MD, as CEO, effective from 2 January 2023, when he will take over from...
Scandion’s Q322 results provided an update on management’s continued commitment to execute on SCO-101’s clinical development strategy.
Redeye comments on Scandion Oncology’s Q3 2022 report, some one month after the company has recruited the first of up to 36 patients to its ...
Redeye adjusts its financial and fair value estimates following Scandion’s conference call on CORIST part 2 top-line data.
Redeye comments on Scandion communicating CORIST part 2 top-line results.
Redeye comments on Scandion’s Q2 2022 report, coming shortly before the company plans to communicate CORIST part 2 top-line data.
Redeye comments on the outcome of Scandion’s rights issue, and we resume our coverage.
Scandion Oncology is a Danish biotechnology company that specialises in developing drugs to reverse chemotherapy resistance.
Redeye briefly comments on Scandion’s rights issue.
Redeye comments on Scandion’s fourth quarter report for 2021, going into an important year for the company.
Redeye briefly comments on Scandion receiving approval for its amended CORIST phase II part 2 proof-of-concept arm.
Redeye comments on Scandion announcing the conclusion of its immuno-oncology collaboration with Alligator Biosciences.
Redeye supports Scandion receiving approval to expand PANTAX phase Ib to Germany.
Redeye comments on Scandion’s Q2‘21 report, following an eventful quarter.
